Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511262 · ClinicalTrials.gov registry record
Detection of Mycoplasma Pneumoniae
A clinical trial, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 471
- Enrollment target
NCT02511262: Completed study, sponsored by Meridian Bioscience.
NCT02511262 is a clinical trial that has completed, run by Meridian Bioscience. The registered enrollment target is 471 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02511262 has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 471 participants
- Enrollment target
Study Summary
The objective of this Clinical Trial is to define the methods to be used to document that illumigene® Mycoplasma Direct meets its intended use claims, using the illumipro instrument, with throat swab samples collected from symptomatic patients.
Primary Outcome
Testing of each enrolled subject's samples will be performed within 14 days of collection.
Interventions
- DEVICE illumigene® Mycoplasma Direct, illumipro-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2015-08 |
What the finished NCT02511262 record still lists
NCT02511262 is an observational study that tracks outcomes without assigning an intervention. The registered 471 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which illumigene® Mycoplasma Direct, illumipro-10 is the first listed.
NCT02511262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02511262 about?
NCT02511262 is a clinical study titled "Detection of Mycoplasma Pneumoniae". The objective of this Clinical Trial is to define the methods to be used to document that illumigene® Mycoplasma Direct meets its intended use claims, using the illumipro instrument, with throat swab samples collected from symptomatic patients.
What is the current status of trial NCT02511262?
This trial is currently completed. The enrollment target is 471 participants. The study started on 2015-08.
What interventions are being tested in trial NCT02511262?
The interventions under investigation include: illumigene® Mycoplasma Direct, illumipro-10 (DEVICE).
Who is sponsoring clinical trial NCT02511262?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03010150 · 471 participants
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- NCT05201404 · 471 participants · Phase 3
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia